StockIQpro
NASDAQ:OTLK

Outlook Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Outlook Therapeutics, Inc.'s revenue was $1.4M in fiscal 2025. The diluted share count rose 87.6%.Summary generated from Outlook Therapeutics, Inc.'s SEC filings. Latest annual report filed Dec 19, 2025.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$1.4M
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross margin4.0%
Operating margin−4744.3%
Net margin−4416.2%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+87.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/a1
Operating income−52−63−53−72−67
Net income−53−66−59−75−62
Free cash flown/an/an/an/an/a

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)